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the inferior vena cava – case report and literature
review
Lukasz Fulawka1,2*, Dariusz Patrzalek3 and Agnieszka Halon1Abstract:
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an incidence rate of 1 to 2 per million person-years.
ACC most commonly arises sporadically, but may be associated with familial tumour syndromes. Clinical symptoms
are mainly related to an excess of steroid hormones. We present an unusual case of adrenocortical carcinoma in
a 27-year-old male who complained of non specific mass-effect related symptoms of slowly growing intensity differing
from others described in literature because of the patient’s age and the sudden deterioration of the clinical course.
The tumour was resected with the left kidney with an extension into the inferior vena cava. Histological examination
revealed morphological features characteristic of an adrenal cortical tumour. The immunohistochemical results (positive
reactions for vimentin, CD56, inhibin, melan A, synaptophysin, bcl-2, calretinin) confirmed the diagnosis. According to
the most widely used modified Weiss criteria and the Van Slooten system, a diagnosis of adrenal cortical carcinoma
was strongly confirmed. The postoperative condition was poor. Reoperation was conducted, including abdominal aorta
thrombectomy and aortic prosthesis implantation. The patient died two days after the second operation. Autopsy
revealed a metastatic tumour in the left lung and morphological symptoms of acute circulatory collapse due to a
massive haemorrhage into the abdominal cavity, which was the direct cause of death.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1602226377106882.
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Van Slooten criteriaBackground
Adrenocortical carcinoma (ACC) is a rare endocrine ma-
lignancy with an incidence rate of 1 to 2 cases per million
person-years [1-3]. It most commonly occurs in two age
groups: the under fives, and 40–59, and is twice as com-
mon in women [1-6]. Most ACC cases are sporadic. How-
ever, familiar neoplasms also exist, most commonly
associated with multiple endocrine neoplasia type 1
(MEN-1), Li-Fraumeni syndrome, Beckwith-Wiedemann
syndrome and Carney complex [1,6].
Clinical symptoms are related to hormonal dysfunction,
which occurs in 60–80% of cases [1,4,6]. Most commonly* Correspondence: lukasz.fulawka@gmail.com
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reproduction in any medium, provided the orit is glucocorticoid or both glucocorticoid and androgen
hypersecretion [1,4,6]. Glucocorticoid-secreting adreno-
cortical tumours are responsible for the minority
(10–15%) of endogenous Cushing syndrome [7]. It is man-
ifested by central obesity, skin-thinning, muscle atrophy,
osteoporosis, immunodeficiency, diabetes and hyperten-
sion [1]. Androgen excess in women results in virilization.
Cases secreting only or predominantly androgen are not
uncommon [1]. Estrogen oversecretion may lead to
gynecomastia in men and metrorrhagia in postmeno-
pausal women. Exceptionally, ACC produces aldosteron
leading to hypertension and hypokalaemia [1,4,6]. Cases
with nonfunctional tumours may have mass-effect related
symptoms or may be discovered as incidentalomas [1,6].
ACCs are generally large tumours, with an average
diameter of 5–20 cm and mass of 1000 g [1,2,6]. Ac-
cording to some authors, they are most commonlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Surgical operation. (A) Large mass of the left adrenal gland revealed in laparotomy (circle). (B) Tumourectomy. (C) Tumour after
resection. (D) Thrombectomy of the inferior vena cava (arrowed).
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tumour mass extending beyond the adrenal gland and
metastases (most commonly lungs, liver or lymph nodes)
[1,6,8]. Five-year survival of patients with ACC varies
from 30 to 45% [2].
In this paper we report the case of an adrenocortical
carcinoma extending into the inferior vena cava and me-
tastasis to a lung, with a fatal outcome.Clinical presentation and management
A 27-year-old male with insulin-dependent diabetes had
been complaining of intensifying stomach fullness, pain
and nausea for two years. The patient was admitted to a
surgery ward with a radiologically identified tumour of
the left kidney and adrenal gland.
Laparotomy was conducted by excision under the left
costal arch. A large adrenal gland tumour was revealed
(Figure 1A). The left kidney and renal vessels were melted
into the tumour mass, and the spleen was bound to it. The
whole tumour was resected with the left kidney (Figures 1B,
1C). A splenectomy was performed, and a thrombectomy
of the inferior vena cava was conducted (Figure 1D).
After surgery the patient was transferred to an inten-
sive care ward with symptoms of MODS (multiple organ
dysfunction syndrome). Despite intensive medication
(catecholamines infusion, mechanical ventilation, di-
uretics infusion, fluid replacement, blood transfusion
and targeted antibiotic therapy), no improvement in
clinical condition was observed. A computed tomog-
raphy angiography revealed critical obstruction of the
abdominal aorta. An urgent relaparotomy was con-
ducted. This was followed by abdominal aorta thrombec-
tomy and aortic prosthesis implantation. After surgery,the patient’s clinical condition continued to deteriorate,
and he died two days after the second operation.Macroscopy of surgical specimen
A surgical specimen was taken which measured 22 × 17 ×
10 cm (Figure 1C). The fat tissue adjacent to the su-
perior pole of the left kidney revealed a solid grey-yellow
tumour measuring 17 × 12 cm, which disintegrated on
palpation. Serial sectioning of the borderline between
tumour and kidney showed the tumour mass reaching
the fibrous capsule of the kidney without evident infil-
tration of the kidney cortex. Sections of the vessels con-
tained emboli. Besides the tumour mass, other surgical
specimens were examined. The first contained the
tumour thrombus from the inferior vena cava. The sec-
ond contained paraaortic and retroperitoneal lymph
nodes. There were 8 lymph nodes in total.Autopsy results
On autopsy, 200 ml of haemorrhagic fluid was revealed
in the peritoneal cavity. The peritoneal surface was cov-
ered with numerous thrombi. Condensation of thrombi
was apparent in the area of tumour bed and aortic pros-
thesis. Dissection of the inferior vena cava revealed a
grey mass bound to its wall in the area of prior surgical
excision. The left pleural cavity contained 1000 ml of
yellowish transparent fluid, the right pleural cavity 600
ml. On pressure, pinkish-yellow slightly foamy liquid
came out from sectional area of both lungs. Left lung
dissection revealed a solid whitish well-circumscribed
tumour of 2 cm in diameter in the superior lobe. The
bronchi of both lungs contained a thick transparent se-
cretion. Dissection of the pericardial cavity revealed 80
Figure 2 Histopathology. (A) Predominant solid area consisted of cells separated by fibrous bands forming fine lobules. (B) Broad fibrous bands
dividing the tumour into prominent lobules. (C) Nest of cells separated by a fine vascular network. (D) Clear-cytoplasm cells forming broad
trabeculae. (E) Capsular invasion. (F) Tumour infiltrating renal capsule without renal tissue invasion (renal cortex visible on the left). (G) Central
part of the tumour with a large haemorrhage. (H) Medium-diameter artery cross-section obliterated with necrotic tumour mass. (I) Thrombus
from the inferior vena cava consisting of tumour mass with necrosis, intermingled with fibrin.
Figure 3 Histopathology-cytologic features. (A) Marked nuclear atypia manifested by significant anisokaryosis and poikilokaryosis. Monster
cells with large nuclei. A few of them create syncytial structure. (B) Atypical mitosis (arrowed).
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showed flattened gyri and obliteration of sulci.
To summarize, the autopsy revealed symptoms of
acute circulatory collapse due to massive haemorrhage
from the tumour bed and from the site of the aortic
prosthesis implantation.
Histopathology
On scanning view the tumour architecture was predomin-
antly solid (Figure 2A). Barely visible fibrous bands sepa-
rated the tumour mass into fine lobules. Considerable
area was divided by broad fibrous bands into prominent
lobules (Figure 2B). Medium magnification revealed a
nests of cells separated by a fine vascular network
(Figure 2C). A minority of the tumour area represented a
broad-trabecular pattern (Figure 2D), and was predomin-
antly composed of clear-cytoplasm cells. Overall, clear
cells made up no more than 25% of the whole tumour
area. Capsular invasion was visible (Figure 2E). The
tumour infiltrated the renal capsule without renal tissueFigure 4 Ki67 immunohistochemistry. Proliferation index, PI =
46% (assessed with ImmunoRatio application [9]).invasion (Figure 2F). Necrosis occupied a significant area
of the tumour. In the central part of the tumour a large
haemorrhage was visible (Figure 2G). Small- and medium-
diameter vessel cross-sections unveiled obliteration with
necrotic tumour masses (Figure 2H). High-power magnifi-
cation revealed significant atypia manifested by prominent
anisokaryosis and poikilokaryosis (Figure 3). The nuclei
were hyperchromatic with coarse chromatin. There were
a few foci of monster cells with huge nuclei, a few of them
forming syncytia (Figure 3A). The proliferation index (PI)
was 46% (assessed with ImmunoRatio web application [9],
Figure 4). Mitotic index (MI) was 22 per 10 high power
fields (HPF). A few atypical mitoses were encountered
(Figure 3B).
The tumour cells showed strong diffused immunoreac-
tivity for vimentin, synaptophysin, CD56 and inhibin
(Figure 5). A significant number of cells were moderate-
to-strong calretinin positive and moderately Bcl-2 posi-
tive. Melan A expression was diffusely positive. A few
scattered cells among the tumour mass revealed weak
chromogranin A immunoreactivity (Figure 5H). The
tumour cells were EMA and S100 negative.
Histopathological examination of the thrombus from
the inferior vena cava revealed a tumour mass with ne-
crosis, intermingled with fibrin (Figure 2I). Sections of
the regional lymph nodes showed reactive changes with-
out any metastases. Microscopic examination of the lung
tumour revealed a solid pattern similar to the predomin-
ant area of the primary tumour with cell nests and a vas-
cular network.
Discussion
In this paper we present the case of an adrenal cortical
carcinoma in a 27-year-old male. According to the litera-
ture peak incidence occurs in the forties and fifties [6].
Family history of endocrine malignancy was negative,
and so genetic tests for hereditary syndromes associated
with increased risk of adrenal cortical malignancy were
deemed unnecessary. Our case probably belonged to the
predominant group of sporadic ACC. The patient pre-
sented symptoms relating to mass effect (stomach full-
ness, pain and nausea). The same manifestations have
been reported by other authors [4,5]. There were no
signs of adrenal gland hormonal dysfunction as occurs
in 60–80% of cases [1,4,6]. The patient had suffered
from insulin-dependent diabetes. However we were un-
able to find any pathogenetic link between diabetes mel-
litus type 1 and non-functional ACC in the literature.
Our surgical specimen measured 22 cm at the largest
diameter, consistent with that described previously
[1,2,6]. The tumour thrombus was present in the inferior
vena cava. According to Icard et al., vena cava thrombec-
tomy was conducted in 6% of 253 cases [2]. The prob-
able source of the thrombus were invaded suprarenal
Figure 5 Immunohistochemistry. (A) Vimentin. (B) Synaptophysin. (C) Calretinin. (D) Inhibin. (E) Melan A. (F) CD56. (G) Bcl2. (H) Chromogranin
A. (I) S100.
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examination.
According to AJCC [10] the tumour was classified
as pT3. This category encompasses tumours of any
size with local invasion, not invading adjacent organs.
In this case the tumour infiltrated its own capsule
and the renal capsule but without invading the renal
cortex. The N category was staged as pN0 with no
metastases revealed on microscopic examination of
regional lymph nodes. Autopsy revealed a tumour in
the superior lobe of the left lung. Microscopically the
lesion revealed a solid pattern, consistent with the
primary tumour histology. Thus the category pM1
was applied. Summarizing, the case was placed into
stage IV, according to AJCC [10]. There are discrep-
ancies in the statistics quoted by different authors.
According to Correa et al. cited by the WHO Classifi-
cation of Tumours [1,8] the majority (40%) of ACC
cases are diagnosed as a stage IV disease. Lafemina
states that 61% of ACCs are stage IV [6]. On theother hand, 21.3% of 253 cases in the Icard study [2]
were stage IV, while 49.8% were stage II.
The most common adrenal gland tumours are meta-
static, as it is the fourth most frequent site of malig-
nancy spread [1]. The most common sources are
primary tumours of breast, lung, kidney, stomach, pan-
creas, ovary and colon [1]. It is therefore important to
take any secondary malignancy into account during the
initial examination of an adrenal tumour. Most are easy
to distinguish on routine hematoxylin-eosin staining.
However, some metastatic tumours can mimic adreno-
cortical neoplasm. Renal cell carcinoma is of special
interest, because its pattern is often similar to that of an
adrenocortical tumour. In this regard a panel of immu-
nohistochemical assays should be implemented in every
suspected adrenal tumour case. This will also help dis-
tinguish adrenal cortical from medullary tumours.
On scanning magnification the tumour had a lobular
structure with large solid areas separated by broad fibrous
bands, consistent with that described as characteristic for
Table 1 Immunophenotype of our case compared to the
literature
Immunohistochemistry Our case Data in the
literature
References
Vimentin (+) (+) [11]
Synaptophysin (+) (+) [11]
Calretinin (+) (+) [1,15]
Inhibin (+) (+) [1,11,12,15]
Melan A (+) (+) [1,11,13,15]
CD56 (+) (+) [11]
Bcl-2
(+) (+) [11,16]
(+) in 30% of cases [11,15]
Chromogranin A (−/+) -
focally
(−) [1,11]
EMA (−) (−) [1,11]
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were broad trabecules. Under medium magnification the
solid areas turned out to be nests of cells separated by a
fine vascular network, a feature characteristic of ACC [1].
To confirm the diagnosis, immunohistochemical as-
says were conducted (Table 1). Tumour cells were
vimentin, synaptophysin, calretinin, inhibin, CD56 and
melan A-positive, consistent with the literature
[1,11-15]. A significant number of cells revealed moder-
ate bcl-2 immunoreactivity. There are discrepancies in
bcl-2 expression quoted in the literature. Fogt et al. saw
a bcl-2 reaction in all 14 adrenocortical carcinomas [16].
Meanwhile, a newer study conducted by Zhang et al.
produced almost the opposite results, with 3 bcl-2 positive
ACC cases out of total of 10 [15]. A few scattered cells
among the tumour mass revealed a weak chromogranin-A
reaction. The accessible sources all state consistently that
chromogranin A immunoreactivity is negative in all casesTable 2 Weiss criteria with Aubert’s modifications for
distinguishing adrenal cortical carcinoma from
adenoma [17]
Weiss criteria Our case




MI (mitotic index) >5/50 HPF +
Atypical mitoses +
Clear cells <25% +





Total Weiss score 9of adrenocortical tumours [1,11]. The tumour cells were
EMA-negative, consistent with the literature [1,11].
There are still no unequivocal recommendations to
distinguish benign and malignant adrenocortical tu-
mours. A few systems encompassing histological criteria
exist. The most commonly appreciated are Weiss criteria
modified by Aubert [17]. Our case fulfilled all the cri-
teria, which was significantly beyond 3, the threshold for
identifying malignant behaviour (Table 2). Another
method for distinguishing adrenocortical adenoma and
carcinoma is the Van Slooten system [18]. All the criteria
were fulfilled (Table 3). Summing all the values, the total
score was 28.4, significantly higher than the score of 8
required to diagnose a malignant adrenocortical tumour.
Histologically, our case presented highly atypical fea-
tures with deeply pleomorphic areas. In this respect, it
was important to search scrupulously for possible sar-
comatous differentiation. To our knowledge, nine cases
of adrenocortical carcinoma containing a component of
sarcoma have been published [3]. Spindle-cell differenti-
ation, consistent with sarcomatous differentiation, was
not revealed in our case.Conclusions
In this paper we report the case of an adrenocortical car-
cinoma (ACC) in a 27-year-old patient, a rare malig-
nancy usually occurring in the 40–59 age group.
Clinically it was characterized by non-specific symptoms
of slowly growing intensity related to mass effect. On
the other hand, pathological examination revealed a
high-stage metastatic tumour of high malignancy. The
postoperative condition was poor. A relaparotomy was
conducted, including abdominal aorta thrombectomy
and aortic prosthesis implantation, but the patient died
two days after the second operation. The direct cause of
death was acute circulatory collapse due to a massiveTable 3 Van Slooten criteria for distinguishing a malignant
adrenal cortical neoplasm from a benign one [18]
Van slooten criteria Value Our case









Nuclear hyperchromasia 2.6 +
Abnormal nucleoli 4.1 +
MI (mitotic index) >2/10 HPF 9.0 +
Capsular/vascular invasion 3.3 +
Total Van Slooten score 28.4
Fulawka et al. Diagnostic Pathology 2014, 9:51 Page 7 of 7
http://www.diagnosticpathology.org/content/9/1/51haemorrhage into the abdominal cavity as revealed by
autopsy.
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